| DB ID | MyCo_2555 |
| Title | (1→3)-β-D-glucan and galactomannan testing for the diagnosis of fungal peritonitis in peritoneal dialysis patients, a pilot study |
| Year | 2015 |
| PMID | 25851260 |
| Fungal Diseases involved | Fungal Peritonitis |
| Associated Medical Condition | Peritoneal dialysis patients |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Peritoneal dialysis fluid (PDF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | As a cross-sectional analysis, all first cloudy peritoneal dialysates from all peritonitis patients seen between January 2013 to April 2014 in Supprasitthiprasong tertiary hospital and King Chulalongkorn Memorial hospital were analyzed for cell count and kept at−80◦C in beta glucan-free containers. A comparative cross-sectional analysis of peritoneal dialysis fluid (PDF) BG (Fungitell, Cape Cod, MA, USA) and GM (Platelia Aspergillus Ag kits, Bio-rad, France) from all PD patients with and without fungal peritonitis (13 cases, identified by culture), over a 1 year period, was performed. |
| Cohort No. | 13 |
| Age Group | None |
| P Value | p<0.05 |
| Sensitivity | 0.77 |
| Specificity | 0.58 |
| Positive Predictive Value | 0.5 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Fungal peritonitis, although an uncommon complication of peritoneal dialysis (PD) patients, has a high mortality and morbidity rate. More than half of PD patients with fungal peritonitis require a change in their mode of renal replacement therapy due to the alteration of peritoneal membrane functions. It is hypothesized that fun- gal penetration into the peritoneum occurs due to its over growth in gastrointestinal tract. Appropriate screening tests may facilitate an early diagnosis of fungal peritonitis leading to earlier antifungal therapy and therapeutic outcome improvement. |
| Technique | Immunological assay |
| Analysis Method | ELISA Based |
| ELISA kits | GM-ELISA Kit (Platelia Aspergillus Ag kits, Bio-rad, France) |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | GM-Platelia Aspergillus Ag Immunoassay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
